SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales slipped to Rs. 2482.91 millions for the December 2021 quarter as against Rs. 3111.83 millions during the year-ago period.The Net Loss for the quarter ended December 2021 is Rs. -235.00 millions as compared to Net Profit of Rs. 304.26 millions of corresponding quarter ended December 2020Operating profit Margin for the quarter ended December 2021 slipped to -18.07% as compared to 449.65% of corresponding quarter ended December 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 2482.91 3111.83 -20.21 6660.61 8628.86 -22.81 11239.73 9044.41 24.27
Other Income 150.89 133.24 13.25 329.70 424.65 -22.36 473.71 991.70 -52.23
PBIDT -18.07 449.65 -104.02 -230.76 1101.38 -120.95 1428.38 85.59 1568.86
Interest 3.29 6.09 -45.98 14.78 9.31 58.75 13.01 12.82 1.48
PBDT -21.36 443.56 -104.82 -245.54 1092.07 -122.48 1415.37 72.77 1844.99
Depreciation 213.64 187.50 13.94 619.20 559.89 10.59 758.92 710.90 6.75
PBT -235.00 256.06 -191.78 -864.74 532.18 -262.49 656.45 -638.13 -202.87
TAX 0.00 -48.20 0.00 -137.11 0.00 0.00 115.63 -74.96 -254.26
Deferred Tax 0.00 0.00 0.00 -139.48 0.00 0.00 109.43 -74.96 -245.98
PAT -235.00 304.26 -177.24 -727.63 532.18 -236.73 540.82 -563.17 -196.03
Equity 140.81 140.81 0.00 140.81 140.81 0.00 140.81 140.81 0.00
PBIDTM(%) -0.73 14.45 -105.04 -3.46 12.76 -127.14 12.71 0.95 1242.95

Unichem Lab Share Price

350.85 4.85 (1.40%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×